Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Savient Shifts Focus To Puricase Submission For Refractory Gout

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm restructures its commercial operations and terminates 19-rep sales force detailing its anabolic agent Oxandrin.

You may also be interested in...



Watson Launches Authorized Oxandrin Generic

Launch follows denial of Savient’s motion for preliminary injunction to prevent Sandoz and Upsher-Smith from launching generic oral anabolic agent.

TAP To Discuss Gout Treatment With FDA Following Second “Approvable” Letter

Febuxostat would be the first new treatment for chronic gout in more than 40 years.

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.

Topics

UsernamePublicRestriction

Register

PS065147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel